Improving HIV medication adherence among Brazilian youth
Making Universal, Free-of-charge Antiretroviral Therapy Work for Sexual and Gender Minority Youth in Brazil
NA · Brown University · NCT06056037
This study is testing a new technology-based counseling program to help young people in Brazil who are living with HIV stick to their medication better.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 72 (estimated) |
| Ages | 18 Years to 24 Years |
| Sex | Male |
| Sponsor | Brown University (other) |
| Locations | 1 site (Rio de Janeiro) |
| Trial ID | NCT06056037 on ClinicalTrials.gov |
What this trial studies
This study aims to develop and pilot a technology-based counseling intervention to enhance adherence to antiretroviral therapy (ART) among sexual and gender minority young people living with HIV in Rio de Janeiro, Brazil. The intervention focuses on improving social support, self-efficacy, and problem-solving skills related to medication adherence. It is informed by focus groups and interviews with SGM youth and healthcare providers to ensure it addresses specific barriers faced by this population. Participants will receive either the experimental intervention or standard care.
Who should consider this trial
Good fit: Ideal candidates for this study are sexual and gender minority individuals aged 18-24 who are living with HIV and currently taking ART.
Not a fit: Patients who do not identify as sexual or gender minorities or those who have not been prescribed ART may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve ART adherence and health outcomes for young people living with HIV in Brazil.
How similar studies have performed: Other studies have shown success in improving ART adherence through targeted interventions for similar populations, indicating a promising approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * between 18 and 24 years of age * assigned male sex at birth * identify as a gay or bisexual man, or a transgender woman or another gender identity along the feminine spectrum * self-report living with HIV, and verified by medical chart review, * self-report currently taking or prescribed ART for \> 3 months * self-report missing 2 or more doses of ART medications in any given week in the past month OR not virally suppressed (i.e., \>40 copies/mL in past 3 months; via national outpatient data \[SISCEL\] or plasma viral load testing) * owns a cell phone or willing to use one as part of the study Exclusion Criteria: * unable to give informed consent due to cognitive limitation, severe mental/physical illness or intoxication * unable to read and/or write to an extent that would limit their ability to comprehend the informed consent * lived in the greater Rio de Janeiro area for \< 3 months or planning to move outside the area within the next year
Where this trial is running
Rio de Janeiro
- Evandro Chagas National Institute of Infectious Diseases (INI) Oswaldo Cruz Foundation (FIOCRUZ) — Rio de Janeiro, Brazil (RECRUITING)
Study contacts
- Principal investigator: Katie Biello, PhD, MPH — Brown University
- Study coordinator: Katie Biello, PhD, MPH
- Email: katie_biello@brown.edu
- Phone: 4018634082
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hiv, Adherence, Medication, Brazil, sexual and gender minority, adolescents, HIV, Medication adherence